```html

Zygomycosis Facial Swelling

What is Zygomycosis facial swelling?

Zygomycosis (also called mucormycosis) is a rare but aggressive fungal infection caused by molds in the order Mucorales. When the infection involves the nose, sinuses, or facial tissues it can produce rapid, painful swelling of the face—often called “facial zygomycosis” or “rhinocerebral mucormycosis.” The fungi invade blood vessels, leading to tissue necrosis (death) and can spread to the eyes, brain, or lungs if not treated promptly.

Although it accounts for less than 1 % of all invasive fungal infections, its high mortality (up to 50 % in some series) makes early recognition essential [Mayo Clinic].

Common Causes

Facial swelling from zygomycosis does not arise spontaneously; it usually follows one of several pre‑disposing conditions that weaken the body’s ability to fight the fungi.

• Uncontrolled Diabetes Mellitus – especially with ketoacidosis.
• Hematologic malignancies – leukemia, lymphoma, or myeloma.
• Stem‑cell or organ transplantation – immunosuppressive drugs increase risk.
• Prolonged neutropenia – low neutrophil counts after chemotherapy.
• Chronic corticosteroid use – high‑dose steroids depress immunity.
• Traumatic facial injuries or surgical debridement – provide a portal of entry.
• Severe burns or wound contamination – especially with soil or debris.
• Iron overload or iron‑chelation therapy (e.g., deferoxamine) – fungi use iron to grow.
• COVID‑19 infection – especially in patients treated with steroids or with uncontrolled diabetes (a surge in mucormycosis was reported in India during 2020‑2022) [CDC].
• Environmental exposure – inhalation of spores from decaying organic matter, compost, or soil.

Associated Symptoms

Facial swelling rarely occurs in isolation. The infection typically produces a constellation of signs that evolve quickly (often within hours to days):

• Painful, firm swelling of the cheek, periorbital area, or nasal bridge.
• Black or necrotic tissue (eschar) inside the nose or palate.
• Fever, chills, or general feeling of illness.
• Headache, especially behind the eyes.
• Sinus congestion or purulent nasal discharge.
• Vision changes – blurry vision, double vision, or sudden loss of sight.
• Facial numbness or paresthesia (tingling).
• Dental pain or loosening of upper teeth.
• Neurologic signs – confusion, seizures, or weakness if the infection spreads to the brain.

When to See a Doctor

Because rhinocerebral mucormycosis can progress to life‑threatening complications within 24‑48 hours, any of the following warrants immediate medical evaluation:

• Rapidly enlarging facial or cheek swelling, especially if painful.
• Black, crusted lesions inside the nose or on the palate.
• Sudden vision changes or eye pain.
• High fever (>38 °C / 100.4 °F) with facial swelling.
• Neurologic symptoms such as confusion, speech difficulty, or weakness.
• History of diabetes, recent chemotherapy, organ transplant, or high‑dose steroids combined with any facial swelling.

If you have any of these signs, seek care at an emergency department or urgent care center right away.

Diagnosis

Diagnosing facial zygomycosis requires a combination of clinical suspicion, imaging, and laboratory confirmation.

1. Clinical Evaluation

Doctors will ask about risk factors (diabetes, immunosuppression, recent COVID‑19) and perform a thorough head‑and‑neck exam, looking for necrotic tissue, tenderness, and cranial nerve deficits.

2. Imaging Studies

• CT Scan of the sinuses and facial bones – identifies bony erosion, sinus opacification, and soft‑tissue swelling.
• MRI with contrast – superior for detecting early spread into the orbit or brain and for visualizing vascular involvement.
• CT Angiography – may be ordered if there is suspicion of vessel invasion or thrombosis.

**3. Laboratory & Pathology**

• Direct microscopy (KOH prep) and culture of nasal or tissue biopsies – shows broad, ribbon‑like, non‑septate hyphae characteristic of Mucorales.
• Histopathology – tissue stained with H&E or PAS reveals angio‑invasive hyphae.
• Serum tests – while there is no specific blood test for mucormycosis, a CBC, metabolic panel, and serum iron may help assess risk.
• Molecular methods (PCR) – increasingly used in specialized labs for rapid species identification.

**4. Staging**

Once confirmed, clinicians stage the disease (e.g., limited to sinuses vs. orbital or cerebral involvement) to guide treatment intensity. The European Confederation of Medical Mycology (ECMM) classification is frequently used.

Treatment Options

Treatment is multimodal and must begin as soon as possible. Delays of even a few hours can worsen outcomes.

1. Medical Therapy

• First‑line antifungal: Liposomal Amphotericin B (5–10 mg/kg IV daily). It penetrates tissues well and is less nephrotoxic than conventional amphotericin.
• Alternative/Step‑down agents – Posaconazole or Isavuconazole can be used after initial control or if amphotericin is intolerable.
• Adjunctive therapy – Management of underlying conditions (e.g., insulin for diabetic ketoacidosis, reduction of steroids).

2. Surgical Management

Because the fungus invades blood vessels and causes tissue death, surgery to remove necrotic tissue is essential.

• Endoscopic sinus debridement for early disease.
• More extensive facial or orbital exenteration for advanced cases.
• Repeated debridements are often required until all non‑viable tissue is cleared.

3. Supportive Care

• IV fluid and electrolyte management (especially in diabetic ketoacidosis).
• Blood glucose control with insulin infusions.
• Pain control and wound care.
• Monitoring renal function during amphotericin therapy.

4. Home Care After Discharge

• Continue oral antifungal (posaconazole or isavuconazole) for 3–6 months as directed.
• Regular follow‑up appointments with an infectious disease specialist and ENT surgeon.
• Daily wound cleaning, use of saline rinses, and prompt reporting of new pain or discoloration.

Prevention Tips

While you cannot control environmental exposure to fungal spores, you can reduce the risk of invasive disease by managing underlying health factors.

• Maintain tight glycemic control – aim for HbA1c <7 % and treat ketoacidosis promptly.
• Avoid unnecessary corticosteroids – use the lowest effective dose for the shortest time.
• Follow infection‑control protocols after surgeries, burns, or trauma; keep wounds clean and covered.
• Limit exposure to dusty or moldy environments if you are immunocompromised; wear a mask when handling soil, compost, or decaying vegetation.
• Stay up‑to‑date with vaccinations (including COVID‑19) to reduce the chance of severe illness that may require high‑dose steroids.
• For transplant or chemotherapy patients, adhere to prophylactic antifungal regimens prescribed by your physician.
• Regularly monitor iron levels; deferoxamine should be used cautiously under medical supervision.

Emergency Warning Signs

Key Take‑aways

• Zygomycosis (mucormycosis) is a rare, fast‑moving fungal infection that can cause dangerous facial swelling.
• Uncontrolled diabetes, immunosuppression, and recent COVID‑19 are the biggest risk factors.
• Look for rapid swelling, black necrotic tissue, fever, and eye or neurologic symptoms.
• Seek immediate medical care – delayed treatment increases mortality.
• Management combines high‑dose IV antifungal medication, aggressive surgical debridement, and control of underlying diseases.
• Good diabetes control, judicious steroid use, and wound hygiene are the best preventive strategies.

For the most current recommendations, consult reputable sources such as the Mayo Clinic, the CDC, and the Cleveland Clinic.

```